Vanessa Biotech (VB), a Hamden, Conn.-based biomedical company committed to improving patient quality of life by developing innovative solutions for unmet medical needs, filed a patent application for the novel and promising treatment of inflammatory bowel disease.
The patent was filed on February 20 as a patent cooperation treaty countries (PCT) application, allowing to streamline the intellectual property (IP) protection process and to pursue IP protection in any and all of 155 member states of the treaty.
Inflammatory bowel disease (IBD) is a significant problem affecting developed countries. One of the main symptoms of the disease is diarrhea. IBD is a chronic condition which persists for years and has a huge impact on the quality of life of people suffering from it.
VB believes that efficient and safe medicine for abdominal symptoms of IBD is much needed and will help individuals to better cope with the disease. VB has been developing treatments that address lethal secretory diarrheal diseases under the direction of Dr. Dmitry Kravtsov, VP of Research and Development. “This patent application is a significant step forward for us on our pathway of introducing efficient solutions for patients suffering from IBD,” said Dr. Kravtsov.
About Vanessa Biotech
Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.
P.O. Box 185755
Hamden, Conn. 06518 USA
+1 203 836 8424